Cited by 15Hyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Management and ResearchDiabetes Treatment and Management

Insulin dosing and glycemic outcomes among steroid-treated hospitalized patients

Open access
Bajaj, Mira A., Zale, Andrew D., Morgenlander, William R., Abusamaan, Mohammed S., Mathioudakis, Nestoras·2022·Endocrine Practice

Abstract

Objective To determine the optimal insulin-to-steroid dose ratio for the attainment of glycemic control in hospitalized patients. Methods We retrospectively studied data collected from the electronic health records within an academic medical center from 18 599 patient-days where patients were treated concurrently with insulin and steroids. Multivariate logistic regression analyses, which included demographic and clinical variables, were performed to assess the relationships between the exposures of total and basal insulin-to-steroid ratios and the outcomes of glycemic control (all blood glucose readings on the following patient-day were >70 and ≤180 mg/dL) and hypoglycemia within 3 subgroups of steroid dosing: low (≤10-mg prednisone equivalent dose [PED]), medium (from >10-mg to ≤40-mg PED), and high (>40-mg PED). Results Increased insulin-to-steroid ratio was associated with increased odds of both glycemic control and hypoglycemia. The optimal total insulin-to-steroid ratio for attaining glycemic control was 0.294 U/kg/10-mg PED in the low-dose subgroup, 0.257 U/kg/10-mg PED in the medium-dose subgroup, and 0.085 U/kg/10-mg PED in the high-dose subgroup. The optimal basal insulin-to-steroid ratio was 0.215 U/kg/10-mg PED in the low-dose subgroup, 0.126 U/kg/10-mg PED in the medium-dose subgroup, and 0.036 U/kg/10-mg PED in the high-dose subgroup. Conclusion Increasing insulin-to-steroid ratios are positively associated with glycemic control and hypoglycemia. Our study suggests that approximately 0.3 U/kg/10-mg PED is an optimal dose for low- and medium-dose steroids, whereas approximately 0.1 U/kg/10-mg PED is an optimal dose for high-dose steroids. Further prospective studies are needed to identify insulin regimens that will optimize glycemic control in steroid-treated patients while minimizing the risk of hypoglycemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eprac.2022.05.002

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The prevalence of consistent use of glucocorticoid therapy in hospitalized individuals can approach 10-15%, and these medications can induce hyperglycemia in 56-86% of these individuals with and without preexisting diabetes.

    “The prevalence of consistent use of glucocorticoid therapy in hospitalized individuals can approach 10-15%, and these medications can induce hyperglycemia in 56-86% of these individuals with and without preexisting diabetes (124-126).”

    From 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026 (2026) · cites this paper as [125]

    The Introduction (page not provided) says that more than half of hospitalized patients receiving high-dose steroids developed hyperglycemia and that steroids can precipitate hyperglycemia with or without preexisting diabetes. It does not give the claimed 56–86% range or say that glucocorticoid use approaches 10–15% among hospitalized patients. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 15

  1. [1]Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014; 6(1): 9– 20. 24103089
  2. [2]Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am. 2014; 43(1): 75– 102. 24582093 PMC3942672
  3. [3]van Raalte DH, Diamant M. Steroid diabetes: from mechanism to treatment? Neth J Med. 2014; 72(2): 62– 72. 24659588
  4. [4]Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014; 30(2): 96– 102. 24123849 PMC4112077
  5. [6]Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014; 65(4): 324– 332. 25402408
  6. [8]Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res Clin Pract. 2013; 99(3): 277– 280. 23298665
  7. [9]Kim HN, Mathioudakis N. Management of glucocorticoid-induced diabetes and/or hyperglycemia. In: Matfin G, ed. Endocrine and Metabolic Emergencies. John Wiley & Sons, Ltd; 2018: 616– 631.
  8. [10]w H, Abid MA, Farooq H, Fazil M, Irshad A, Butt A. Incidence and attributing factors of impaired blood glucose in non-diabetic patients on steroid therapy. Ann Pak Inst Med Sci. 2021; 17(3): 232– 235.
  9. [12]Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015; 6(8): 1073– 1081. 26240704 PMC4515447
  10. [14]Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009; 15(5): 469– 474. 19454391
  11. [15]Asare K. Diagnosis and treatment of adrenal insufficiency in the critically ill patient. Pharmacotherapy. 2007; 27(11): 1512– 1528. 17963461
  12. [17]Stone AC, Dungan K, Gaborcik JW. Insulin NPH for steroid-induced hyperglycemia: predictors for success. Pharmacotherapy. 2021; 41(10): 804– 810. 34420221
  13. [22]Khowaja A, Alkhaddo JB, Rana Z, Fish L. Glycemic control in hospitalized patients with diabetes receiving corticosteroids using a neutral protamine Hagedorn insulin protocol: a randomized clinical trial. Diabetes Ther. 2018; 9(4): 1647– 1655. 29961246 PMC6064602
  14. [23]Myers AK, Khan M, Choi S, Garnica P, Stoffels G, Lin A. Implementation of a weight-based protocol for the management of steroid-induced hyperglycemia. Am J Ther. 2020; 27(4): e392– e399. 32628394
  15. [24]Howard-Thompson A, Khan M, Jones M, George CM. Type 2 diabetes mellitus: outpatient insulin management. Am Fam Physician. 2018; 97(1): 29– 37. 29365240

Cited by

Sorted by citations

Authors
Bajaj, M. A., Zale, A. D., Morgenlander, W. R., Abusamaan, M. S., & Mathioudakis, N.
Affiliations
Johns Hopkins University (US)
Corresponding author
Mathioudakis, Nestoras
Venue
Endocrine Practice
Publisher
Elsevier BV
Published
2022-08
Volume
28
Issue
8
Pages
774-779
ISSN
1530-891X (ISSN-L)
OpenAlex
W4229447384
Cited by
15
References
8
Citations by year
2026: 3 · 2025: 5 · 2024: 5 · 2023: 1 · 2022: 1
FWCI
2.22
Type
journal article
Language
en
Open access
Locations
  • Endocrine Practice (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
insulin dose, glycemic control, hypoglycemia, corticosteroid therapy, hospitalized patients, prednisone-equivalent dose, basal insulin, blood glucose
MeSH terms
Blood Glucose, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Inpatients, Insulin, Retrospective Studies, Steroids, Insulin, Regular, Human

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review